Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00516243 · ClinicalTrials.gov registry record · Phase 1
Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer
A Phase 1 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT00516243: Completed Phase 1 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by National Cancer Institute (NCI).
NCT00516243 is a Phase 1 study of Stage II Breast Cancer and Stage IIIA Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 318-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00516243, a Phase 1 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized phase I trial studies the side effects and best dose of defined green tea catechin extract in treating women with hormone receptor-negative stage I-III breast cancer. Green tea extract contains ingredients that may prevent or slow the growth of breast cancer.
Conditions Studied
Interventions
- OTHER placebo
- OTHER quality-of-life assessment
- PROCEDURE laboratory biomarker analysis
- PROCEDURE questionnaire administration
- DRUG defined green tea catechin extract
Study Locations (4)
New York
- Columbia University Medical Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- Baylor College of Medicine - Houston
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
What the finished NCT00516243 record still lists
NCT00516243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 318-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (87% lower).
The record links to 6 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT00516243 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00516243 about?
NCT00516243 is a clinical study titled "Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer". This randomized phase I trial studies the side effects and best dose of defined green tea catechin extract in treating women with hormone receptor-negative stage I-III breast cancer. Green tea extract contains ingredients that may prevent or slow the growth of breast cancer.
What is the current status of trial NCT00516243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-07. Estimated completion is 2010-03.
What conditions does trial NCT00516243 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Estrogen Receptor-negative Breast Cancer.
What interventions are being tested in trial NCT00516243?
The interventions under investigation include: placebo (OTHER), quality-of-life assessment (OTHER), laboratory biomarker analysis (PROCEDURE), questionnaire administration (PROCEDURE), defined green tea catechin extract (DRUG).
Who is sponsoring clinical trial NCT00516243?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00516243 being conducted?
This trial has 4 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00516243's enrollment target sits among peer trials
40 25th of 30 higher than 6 of 30 other Stage II Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage II Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
COMPLETED · Phase 1
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
A Study of Revaree Plus in People With Breast Cancer
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia